The authors compared the survival of four groups of patients and of renal grafts: 1. diabetics after renal transplantation (24 subjects), 2. diabetics after transplantation of the kidney and pancreas (35 subjects), 3. diabetics where transplantation was indicated but who were treated only by dialysis and 4. non-diabetics after transplantation of the kidney (170 subjects). The two-year cumulative survival of the entire group of diabetics regardless of the type of treatment was 59%. The two-year survival of diabetics after transplantation of the kidney alone was 95%, after transplantation of the kidney and pancreas 70% and in non-diabetics after transplantation of the kidney 90%. In diabetics treated by dialysis it was 33%. The two-year survival of the function of renal grafts in the entire group of diabetics treated by transplantation of the kidney was 61%, in non-diabetics 68% and the three-year survival was in both groups 61%. As compared with the EDTA register, the results of transplantation treatment are favourable, the results of dialyzation treatment are poor. From the results the authors draw conclusions for indication of different ways of replacement of renal function in diabetics in relation to the general health status of the patients.
Download full-text PDF |
Source |
---|
PLoS One
January 2025
Department of Kidney Transplantation, Nephropathy Hospital, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaan'xi, China.
Increasing evidence suggests that dysbiosis of gut microbiota exacerbates chronic kidney disease (CKD) progression. Curcumin (CUR) has been reported to alleviate renal fibrosis in animal models of CKD. However, the relationship between CUR and gut microbiome in CKD remains unclear.
View Article and Find Full Text PDFKidney360
January 2025
Department of Pediatrics, Division of Nephrology, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA.
Background: Acute kidney disease (AKD) includes abnormalities of kidney function present for <90 days. Acute kidney injury (AKI) is defined as a subset of AKD, with onset within seven days. There is scant data on the rates of AKD in children and its association with outcomes.
View Article and Find Full Text PDFKidney360
January 2025
Centro Hospitalar Universitário de Coimbra, Nephrology Department, 3004 Coimbra, Portugal.
Hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy for patients with hematologic malignancies and certain solid tumors and nonmalignant hematologic conditions. Both acute kidney injury (AKI) and chronic kidney disease (CKD) occur commonly after HSCT and are associated with significant morbidity and mortality. AKI and CKD in this setting may result from direct effects of the transplant or be caused by pretransplant bone marrow conditioning regimens and/or nephrotoxic agents administered in the post-transplant period.
View Article and Find Full Text PDFJ Racial Ethn Health Disparities
January 2025
Regenstrief Institute, Indianapolis, IN, USA.
African Americans (AAs) with end-stage kidney disease (ESKD) experience significant barriers to accessing living donor kidney transplantation (LDKT), largely due to individual and systemic factors, including a lack of trust in healthcare systems resulting from a legacy of and continued experiences with medical racism. This cross-sectional study analyzed survey data from 416 AA patients with ESKD undergoing transplant evaluation in 2019-2023 at two kidney transplant centers in the Southeast United States, examining whether trust (specifically trust in kidney doctors, hospitals, and healthcare) modifies the relationship between attitudes towards LDKT and behavioral intentions to discuss LDKT with family and friends. Multivariable analyses revealed significant interactions.
View Article and Find Full Text PDFLupus
January 2025
Medical Research Centre, The University of Waikato, Hamilton, New Zealand.
Objectives: This study aims to estimate the annual medical costs of systemic lupus erythematosus (SLE) in New Zealand (NZ).
Methods: SLE patients were linked to the Australia and New Zealand Dialysis and Transplant Registry, Pharmaceutical Collection, National Minimum Dataset, National Non-Admitted Patients Collection and Mortality Collection. National direct medical costs of SLE in 2006-2021 and annual costs per patient were estimated.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!